Capital World Investors
CLDX icon

Capital World Investors’s Celldex Therapeutics CLDX Stock Holding History

Capital World Investors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-41,800
Closed -$9.83M – 495
2015
Q4 		$9.83M Hold
41,800
– – ﹤0.01% 471
2015
Q3 		$6.61M Hold
41,800
– – ﹤0.01% 491
2015
Q2 		$15.8M Hold
41,800
– – ﹤0.01% 459
2015
Q1 		$17.5M Buy
41,800
+16,000
+62% +$5.72M ﹤0.01% 454
2014
Q4 		$7.06M Hold
25,800
– – ﹤0.01% 506
2014
Q3 		$5.02M Hold
25,800
– – ﹤0.01% 498
2014
Q2 		$6.32M Buy
25,800
+6,667
+35% +$1.51M ﹤0.01% 499
2014
Q1 		$5.07M Buy
19,133
+5,800
+44% +$2.22M ﹤0.01% 489
2013
Q4 		$4.84M Buy
+13,333
New +$5.14M ﹤0.01% 472

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors's CLDX Position: Q1 2016 in Review

Capital World Investors sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 41,800 shares — an estimated $9.83M sold.

Capital World Investors first reported a position in CLDX in Q4 2013 and held it in 9 quarters. The position peaked at $17.5M in Q1 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Capital World Investors reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Capital World Investors sold 41,800 Celldex Therapeutics shares in Q1 2016, an estimated $9.83M.
  • Capital World Investors first reported a position in Celldex Therapeutics in Q4 2013 and held it in 9 quarters.
  • Capital World Investors's Celldex Therapeutics position peaked at $17.5M in Q1 2015.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Capital World Investors's 13F filing for Q1 2016, filed 16 May 2016.